Furosemide Stress Test Protocol in AKI
In a non-anuric patient with acute kidney injury (stages 1-2) who has no loop diuretic allergy and is euvolemic, administer 1.0 mg/kg IV furosemide as a single bolus (or 1.5 mg/kg if the patient received loop diuretics within the prior 7 days), then measure hourly urine output for 2-6 hours. 1
Pre-Test Requirements
Before performing the FST, confirm the following:
- Volume status is adequate - The patient must not be volume depleted, as hypovolemia will confound results and potentially worsen kidney function 2
- No sulfonamide allergy - Patients allergic to sulfonamides may cross-react with furosemide 2
- Check baseline electrolytes - Particularly potassium, sodium, magnesium, and calcium, as furosemide can exacerbate existing deficiencies 2
- Assess for urinary retention risk - In patients with prostatic hyperplasia, bladder dysfunction, or urethral narrowing, furosemide may precipitate acute urinary retention 2
Dosing Protocol
The standardized FST dosing is straightforward:
- 1.0 mg/kg IV furosemide for loop diuretic-naive patients
- 1.5 mg/kg IV furosemide if the patient received any loop diuretic within the preceding 7 days 3, 4, 5
Administer as a single intravenous bolus, not as an infusion.
Urine Output Monitoring
Measure urine output hourly for at least 2 hours, ideally extending to 6 hours 3, 6:
- FST-responsive: Urine output >200 mL total at 2 hours (or >2 mL/kg/h in pediatrics) 3, 5
- FST-nonresponsive: Urine output <200 mL at 2 hours
The 2-hour urine output is the primary endpoint, though some protocols extend monitoring to 6 hours for additional prognostic information 6.
Interpretation and Clinical Utility
FST nonresponders have dramatically higher risk of progression to stage 3 AKI and need for renal replacement therapy. The test performs exceptionally well as a functional biomarker 1:
- FST nonresponders are 2.4 times more likely to require RRT compared to responders 3
- The test has an AUROC of 0.87-0.96 for predicting stage 3 AKI 4, 3
- For RRT prediction, AUROC reaches 0.84-0.86 4, 3
- Optimal cutoff for predicting severe AKI: <156 mL total urine output at 2 hours (sensitivity 94.9%, specificity 98.0%) 3
The FST outperforms biochemical biomarkers like NGAL, TIMP-2×IGFBP7, and proenkephalin for predicting AKI progression 4, 5. While combining FST with biomarkers doesn't significantly improve prediction, using FST in patients with already-elevated biomarkers can enhance risk stratification 4.
Critical Caveats
Hypoalbuminemia significantly affects FST response - Patients with severe hypoalbuminemia (<1 g/dL) have markedly reduced response rates to furosemide 7. However, those with mild-to-moderate hypoalbuminemia (albumin 1.4-2.7 g/dL) can still respond adequately without albumin supplementation, with 80% showing appropriate diuretic response 7.
Monitor for complications during and after FST 2:
- Electrolyte depletion (hypokalemia, hyponatremia, hypomagnesemia)
- Excessive diuresis leading to volume depletion
- Ototoxicity risk, especially with concurrent aminoglycosides or in renal impairment
- Drug interactions with ACE inhibitors, ARBs, NSAIDs, or lithium
The FST is contraindicated in:
- Anuric patients (by definition, they cannot respond)
- Volume-depleted patients (correct hypovolemia first)
- Known loop diuretic allergy
Integration into Clinical Decision-Making
Use FST results to guide RRT timing discussions and intensity of monitoring 1. The 2020 KDIGO conference acknowledged that while optimal RRT timing remains controversial, "use of a standardized FST can be considered in AKI to further quantify the likelihood of AKI progression" 1. This functional assessment provides actionable information within 2-6 hours, much faster than waiting for creatinine changes or biomarker results.
FST nonresponders warrant:
- More aggressive monitoring
- Early nephrology consultation
- Preparation for potential RRT
- Avoidance of additional nephrotoxins
- Optimization of hemodynamics and volume status